With 50% of women aged 45-59 years of age experiencing some degree of mild, moderate or severe urinary incontinence and the condition affecting up to 37% of all Australian women, with similar rates across the world. After receiving unexpected positive feedback from customers, we decided to develop a SRC restore garment that would address the 2 conditions of stress urinary incontinence and prolapse. We are just delighted to be able to provide relief for some of the women who are experiencing stress urinary incontinence and receive amazing feedback.
This new innovative product called SRC Restore or Incontinence Underwear is very much in line with our vision and mission as a company, summed up in our slogan “Support for Life”, however it may be seen as a departure from our focus on the pregnancy and postpartum periods of a woman’s life, but in fact it is also used to birthing trauma and other factors associated with pregnancy and recovery.
Read more on urinary incontinence
The global Urinary Incontinence Treatment Drugs Market research report, published by Value Market Research, is designed to offer various market framework such as market size, portion, trends, growth path, value and factors that impact the current market dynamics over the forecast period 2020-2027.
Most importantly, this report also provides the latest significant strategies adopted by major players along with their market share.The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide.
The major players in the urinary incontinence treatment drugs market include Johnson & Johnson, Pfizer Inc., Astellas Pharma, Inc., Allergan, Inc., Takeda Pharmaceutical Company Limited, Merck & Co., Inc., and Sanofi S.A.
This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.Get more information on "Global Urinary Incontinence Treatment Drugs Market Research Report" by requesting FREE Sample Copy at https://www.valuemarketresearch.com/contact/urinary-incontinence-treatment-drugs-market/download-sampleMarket DynamicsUrinary incontinence is one of the most prevalent medical conditions seen in the elderly population.
One-third of females older than 65 years are known to cause urinary incontinence treatment, and 12 % have daily incontinence.
Growing approvals by FDA for new drugs and growing research to develop new medicines is stimulating growth.